TTAP sit-in enters fourth day amid Imran health concerns

Updated 17 Feb, 2026 12:11am
By
A sit-in by the opposition alliance at the Parliament House continued for a fourth consecutive day on Monday. Screengrab
A sit-in by the opposition alliance at the Parliament House continued for a fourth consecutive day on Monday. Screengrab

A sit-in by the opposition alliance at the Parliament House continued for a fourth consecutive day on Monday, with leaders insisting the protest will remain in place until Pakistan Tehreek-e-Insaf (PTI) founder Imran Khan is provided what they describe as adequate medical facilities.

The protest is being led by the Tehreek Tahaffuz-e-Aiyeen Pakistan (TTAP) and PTI lawmakers over concerns about Khan’s health, particularly his eyesight.

National Assembly Opposition Leader Mehmood Khan Achakzai, Senate Opposition Leader Allama Raja Nasir Abbas, PTI Chairman Gohar Ali Khan, former speaker Asad Qaiser and other lawmakers were present at the Parliament House.

In parallel, PTI provincial legislators are holding a sit-in at KP House in Islamabad under the leadership of Khyber Pakhtunkhwa Chief Minister Sohail Afridi.

The opposition alliance has demanded that Khan be allowed an eye examination under the supervision of his personal physician, saying this is necessary to establish the “true facts” regarding his health.

Meanwhile, a medical report submitted to the Supreme Court of Pakistan said Khan has regained nearly 70 per cent of his eyesight following treatment. The preliminary assessment was prepared after a comprehensive eye examination conducted at Adiala Jail and was signed by ophthalmologists Nadeem Qureshi and Muhammad Arif Khan.

According to the report, a medical board comprising specialists from Al-Shifa Trust Eye Hospital and Pakistan Institute of Medical Sciences examined the former prime minister on February 15, 2026.

Doctors noted a marked improvement in vision. Without glasses, vision in the right eye was recorded at 6/24 (partial) and 6/9 in the left eye. With corrective lenses, the right eye improved to 6/9 (partial) and the left eye to 6/6.

Medical findings showed inflammation and disrupted blood flow in the retina of the right eye, but swelling had reduced significantly. Retinal thickness declined from 550 to 350, indicating recovery. Doctors said vision had improved from 6/36 to 6/9 (partial), which they described as satisfactory at this stage.

The board prescribed Nevanac and Systane Ultra eye drops for both eyes and Cosopt drops for the right eye. It also recommended OCT angiography and fundus fluorescein angiography after completion of anti-VEGF therapy.

The report said PTI Chairman Gohar Ali Khan and Allama Raja Nasir Abbas visited PIMS, where doctors briefed them on Khan’s condition. Khan’s personal physicians, Dr Asim Yousuf and Dr Khurram Mirza, were also briefed over the phone for 25 minutes and expressed satisfaction with the progress. In a video message, Dr Yousuf said he had spoken directly with the treating doctors and would verify the findings after conducting his own examination.

Attorney General Mansoor Usman Awan later met Chief Justice Yahya Afridi and briefed him on Khan’s treatment and arrangements, saying the former premier’s eyesight had recovered by about 67 to 70 per cent.

Khan was earlier shifted to PIMS after complaining of severe eye pain, where doctors diagnosed him with central retinal vein occlusion, a condition caused by blockage of a major retinal vein that can lead to swelling, bleeding and loss of central vision.

Following media reports about Khan’s deteriorating eyesight, the Supreme Court appointed Salman Safdar as amicus curiae and directed him to visit Adiala Jail, meet Khan and submit a detailed report.

A two-member bench headed by Chief Justice Yahya Afridi reiterated during Tuesday’s hearing that Safdar must assess Khan’s health condition and the medical facilities available to him in custody and present his findings before the court.

For the latest news, follow us on Twitter @Aaj_Urdu. We are also on Facebook, Instagram and YouTube.